The collaboration aims to expedite the development of new dermatological treatment options. Credit: Kmpzzz / Shutterstock.com.

Pharmaceutical company Almirall has entered a strategic collaboration with Microsoft to steer innovation and digital transformation in dermatology.

The three-year collaboration will leverage generative artificial intelligence (genAI) and advanced analytics to enhance drug discovery and development processes, aiming to bring forward new treatments in medical dermatology.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Microsoft Industry Solutions, Microsoft partners and Almirall will establish a joint “digital office” which will build on the pharma company’s comprehensive data platform.

By combining Almirall’s research and development (R&D) and drug discovery capabilities with Microsoft’s digital technologies, the collaboration aims to expedite the development of new dermatological treatment options.

Almirall CEO Carlos Gallardo stated: “This agreement with Microsoft is a significant advancement in our digital transformation to achieve our goal of delivering novel treatment options for patients.

“It will empower us to apply the latest technologies to transform our ways of working, and accelerate drug discovery.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A significant aspect of the collaboration is the use of genAI for the quick analysis of large datasets, thereby establishing a digital, agile and patient-centric approach within Almirall’s R&D operations.

The goal is to expedite the discovery of new treatment targets and synthesisable molecules, enriching Almirall’s dermatology pipeline.

The alliance is set to streamline operations through data and AI, developing an intelligence-driven technology platform.

AI technologies will be used to select drug discovery projects, focusing on novelty and commercial potential prior to validation.

Microsoft Spain country general manager Alberto Granados stated: “Through this strategic partnership, Microsoft and its industry solutions organisation will collaborate with Almirall towards their goal of becoming the greatest dermatology company ever, revolutionising dermatological treatments and providing patients with the best possible solutions by leveraging Microsoft cutting-edge technologies of advanced analytics and generative artificial intelligence to foster innovation in drug discovery and development.”